ZYBERNO
Stock Report
Updated Aug 26, 2026

CERO THERAPEUTICS HOLDINGS, INC. (CEROW)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
0.0/100
POOR BUSINESS
CERO THERAPEUTICS HOLDINGS, INC. (CEROW) scores 0/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CERO THERAPEUTICS HOLDINGS, INC. (CEROW) stock report — Zyberno Score 0/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$71.70K

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$937.51B

Price Action & Momentum (1)

% of 52-Week High:6.0%
B. Profitability Assessment

Return Metrics (2)

ROA:-559.7%
Reinvestment Rate:0.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$4.22M
Dividend Yield:177.3%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.05x
Quick Ratio:0.05x
Cash Ratio:28,930.85x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-22.93x
Times Interest Earned:-22.93

Capital Structure (4)

Working Capital:-30,857,318.00
Cash And Cash Equivalents:937,512,000,000.00
Long Term Debt:$218.31K
Net Debt:-$937.51B
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$18.94M

Bottom Line Performance (3)

-$16.31M
Income Before Tax:-$308.28K
Ebitda Ttm:-18,861,847.00

Operating Expenses (5)

Operating Expenses:17,778,564.00
R And D Expense:9,214,565.00
Sga Expense:8,563,999.00
Income Tax Expense:$0.00
Interest Expense:868,889.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.90M
Current Assets:$1.55M
Ppe Net:2,554,591.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:32,405,268.00
Current Liabilities:32,405,268.00
Long Term Debt:$218.31K
Short Term Debt:$218.31K

Equity & Capital (3)

Equity:-$30.51M
Retained Earnings:-$97.75M
Common Stock:45,350,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:8,216,774.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,122,085.00
C. Cash Flow Analysis

Operating Activities (2)

-$16.10M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$32.58M
Dividends Paid Ttm:127,144.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,700,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-71.71
-$71.71
Earnings Per Share Ttm:-$0.39

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.38

Book Value & Capital (2)

Book Value Per Share:-$0.72
Cash Per Share:22,229.08

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (1)

Reinvestment Rate:0.5%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:CEROW
Company Name:CERO THERAPEUTICS HOLDINGS, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:42.18M
Shares Outstanding Basic:42.18M
Shares Outstanding Diluted:42.18M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 18:08:08 UTC
Data Timestamp:2026-08-26T18:08:08.029879
Scroll to Top